These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21585279)

  • 21. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
    Lalloyer F; Fiévet C; Lestavel S; Torpier G; van der Veen J; Touche V; Bultel S; Yous S; Kuipers F; Paumelle R; Fruchart JC; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2731-7. PubMed ID: 17008586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.
    Bomben V; Holth J; Reed J; Cramer P; Landreth G; Noebels J
    Neurobiol Aging; 2014 Sep; 35(9):2091-5. PubMed ID: 24767949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bexarotene.
    Am J Health Syst Pharm; 2000 Dec; 57(23):2167. PubMed ID: 11127695
    [No Abstract]   [Full Text] [Related]  

  • 24. Topical and oral bexarotene.
    Schadt CR
    Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway.
    Zhu J; Ning RB; Lin XY; Chai DJ; Xu CS; Xie H; Zeng JZ; Lin JX
    Am J Hypertens; 2014 Aug; 27(8):1112-24. PubMed ID: 24603314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
    Pileri A; Delfino C; Grandi V; Pimpinelli N
    Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
    Yen WC; Lamph WW
    Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central hypothyroidism associated with retinoid X receptor-selective ligands.
    Sherman SI; Gopal J; Haugen BR; Chiu AC; Whaley K; Nowlakha P; Duvic M
    N Engl J Med; 1999 Apr; 340(14):1075-9. PubMed ID: 10194237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
    Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
    J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
    Mirza Z; Beg MA
    Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell lymphoma products.
    Bell TJ
    Nurse Pract; 2001 Mar; 26(3):19. PubMed ID: 11270155
    [No Abstract]   [Full Text] [Related]  

  • 32. The novel function of bexarotene for neurological diseases.
    Liu Y; Wang P; Jin G; Shi P; Zhao Y; Guo J; Yin Y; Shao Q; Li P; Yang P
    Ageing Res Rev; 2023 Sep; 90():102021. PubMed ID: 37495118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
    Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
    Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells.
    Bauer JB; Lippert WP; Dörrich S; Tebbe D; Burschka C; Christie VB; Tams DM; Henderson AP; Murray BA; Marder TB; Przyborski SA; Tacke R
    ChemMedChem; 2011 Aug; 6(8):1509-17. PubMed ID: 21726055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.
    Quéreux G; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Dréno B
    Expert Opin Pharmacother; 2013 Sep; 14(13):1711-21. PubMed ID: 23837676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).
    Schäfer A; Burstein ES; Olsson R
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1944-7. PubMed ID: 24666648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation.
    Chen L; Wang Y; Zhang J; Hao L; Guo H; Lou H; Zhang D
    Eur J Pharm Biopharm; 2014 May; 87(1):160-9. PubMed ID: 24333772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folliculotropic mycosis fungoides responding to bexarotene gel.
    Walling HW; Swick BL; Gerami P; Scupham RK
    J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advances in studies on selective RXR ligands].
    Mei JH; Wang MW
    Yao Xue Xue Bao; 2005 Apr; 40(4):294-8. PubMed ID: 16011254
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.